uniQure gene therapy leads to sustained Factor IX activity in Phase IIb study

uniQure N.V. (NASDAQ:QURE) said Feb. 8 new data showed sustained Factor IX activity in a Phase IIb study of gene therapy AMT-061 to treat hemophilia B. Separately, the company said Feb. 4 it had dosed the first patient

Read the full 389 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE